You can buy or sell SRPT and other stocks, options, ETFs, and crypto commission-free!
Sarepta Therapeutics, Inc. Common Stock (DE), also called Sarepta Therapeutics, is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. Read More The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Market Weekly Review: Lower Prices Create Buying Opportunities
Despite gains for U.S. stocks on Friday, the Dow Jones Industrial Average ended lower for a fifth straight week—which is the longest streak since 2011. After a white-hot start to 2019, it’s been a wild wide for investors in the month of May. As the war of words has progressed in the trade battle between China and the U.S., price volatility has been on the increase. Use Volatility to Your Advantage Investors tend to shy away from volatility, which is a word that generally is only mentioned when prices are...
Seeking AlphaMay 23
Independent research group finds scant evidence of efficacy for Sarepta's exon-skipping DMD meds
A report prepared for the New England Comparative Effectiveness Public Advisory Council (CEPAC) by the Institute for Clinical and Economic Review (ICER), an independent non-profit research organization that evaluates medical evidence, did not find much evidence supporting the efficacy of Sarepta Therapeutics' (NASDAQ:SRPT) Exondys 51 (eteplirsen), golodirsen or PTC Therapeutics' (NASDAQ:PTCT) Emflaza (deflazacort) in the clinical studies conducted to date.
Expected Aug 7, After Hours